Hostname: page-component-76fb5796d-dfsvx Total loading time: 0 Render date: 2024-04-26T06:32:57.643Z Has data issue: false hasContentIssue false
  • English
  • Français

Platelet Monoamine Oxidase Activity in Schizophrenia

Relationship to Disease, Treatment, Institutionalization and Outcome

Published online by Cambridge University Press:  29 January 2018

John Mann  and
K. M. Thomas
John Mann
Affiliation:
Royal Melbourne Hospital; Associate, Department of Psychiatry, University of Melbourne
K. M. Thomas
Affiliation:
Mont Park Psychiatric Hospital
Get access Rights & Permissions [Opens in a new window]

Summary

A study was made of platelet monoamine oxidase (MAO) activity in non-medicated, newly-admitted schizophrenics and institutionalized chronic schizophrenics both on and off medication. These patients were compared to two control groups: normal subjects and brain-damaged institutionalized patients. No relationship was found between platelet MAO activity and the severity or duration of illness, duration of psychotropic medication, presence of auditory hallucinations or institutionalization. Mean platelet MAO activity did not differ significantly between the schizophrenic subgroups and control groups. Thirty-one patients studied before and after treatment with phenothiazines showed no significant change in platelet MAO activity. The findings did not indicate a relationship between schizophrenia, its treatment or outcome and platelet MAO activity.

Type
Papers
Information
The British Journal of Psychiatry , Volume 134 , Issue 4 , April 1979 , pp. 366 - 371
Copyright
Copyright © Royal College of Psychiatrists, 1979 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Becker, R. E. & Shaskan, E. G. (1977) Platelet monoamine oxidase activity in schizophrenic patients. American Journal of Psychiatry, 134, 512–7.Google ScholarPubMed
Berrettini, W. H., Vogel, W. H. & Clouse, R. (1977) Platelet monoamine oxidase in chronic schizophrenia. American Journal of Psychiatry, 134, 805–6.Google ScholarPubMed
Breese, G. R. & Taylor, T. D. (1970) Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective destruction of catecholamine neurons. Journal of Pharmacology and Experimental Therapeutics, 174, 412–20.Google Scholar
Brockington, I., Crow, T. J., Johnstone, E. C. & Owen, F. (1976) An investigation of platelet monoamine oxidase activity in schizophrenia and schizoaffective psychosis. In Monoamine Oxidase and its Inhibition. Ciba Foundation Symposium 39 (new series), pp 353–62. Amsterdam: Associated Scientific Publishers.Google Scholar
Carpenter, W. T., Murphy, D. L. & Wyatt, R. J. (1975) Platelet monoamine oxidase activity in acute schizophrenia. American Journal of Psychiatry, 132, 438–41.Google ScholarPubMed
Domino, E. F. & Khanna, S. S. (1976) Decreased blood platelet MAO activity in unmedicated chronic schizophrenic patients. American Journal of Psychiatry, 133, 323–6.Google ScholarPubMed
Feighner, J. P., Robins, E., Guze, S. B., Woodruff, R. A., Winokur, G. & Munoz, R. (1972) Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry, 26, 57–63.CrossRefGoogle ScholarPubMed
Friedman, E., Shopsin, B., Sathananthan, G. & Gershon, S. (1974) Blood platelet monoamine oxidase in psychiatric patients. American Journal of Psychiatry, 131, 1392–4.CrossRefGoogle ScholarPubMed
Jarrott, B. (1974) Methods for analysing monoamine oxidase and catechol-O-methyltransferase in nervous tissue. In Research Methods in Neurochemistry, vol. 2, pp 377–88 (eds. N. Marks and R. Rodnight). New York: Plenum Press.Google Scholar
Lowry, O. H., Rosebrough, N. J., Farr, A. L. & Randall, R. J. (1951) Protein measurement with the folin phenol reagent. Journal of Biological Chemistry, 193, 265–75.CrossRefGoogle ScholarPubMed
Mandell, A. J. & Segal, D. S. (1973) The psychobiology of dopamine and the methylated indoleamines with particular reference to psychiatry. In Biological Psychiatry (ed. J. Mendels), pp 89–112. New York: John Wiley & Sons.Google Scholar
Mann, J. J. & Chui, E. (1978) Platelet monoamine oxidase in Huntington's chorea. Journal of Neurology, Neurosurgery and Psychiatry, in press.CrossRefGoogle Scholar
Meltzer, H. Y. & Stahl, S. M. (1974) Platelet monoamine oxidase and substrate preferences in schizophrenic patients. Research Communications in Chemical Pathology and Pharmacology, 7, 419–31.Google ScholarPubMed
Murphy, D. L. & Weiss, R. (1972) Reduced monoamine oxidase activity in blood platelets from bipolar depressed patients. American Journal of Psychiatry, 128, 35–41.CrossRefGoogle ScholarPubMed
Murphy, D. L., Wright, C., Buchsbaum, M., Nichols, A., Costa, J. L. & Wyatt, R. J. (1976) Platelet and plasma amine oxidase activity in 680 normals: sex and age differences and stability over time. Biological Medicine, 16, 254–65.Google Scholar
Murphy, D. L. & Wyatt, R. J. (1972) Reduced monoamine oxidase activity in blood platelets from schizophrenic patients. Nature, 238, 225–6.CrossRefGoogle ScholarPubMed
Nies, A., Robinson, D. S., Harris, L. S. & Lamborn, K. R. (1974) Comparison of monoamine oxidase substrate activity in twins, schizophrenics, depressives and controls. Advances in Biochemical Psychopharmacology, 12, 59–70.Google ScholarPubMed
Overall, J. E. & Gorham, D. R. (1962) The brief psychiatric rating scale. Psychological Reports, 10, 799–812.CrossRefGoogle Scholar
Owen, F., Bourne, R., Crow, T. J., Johnstone, E. C., Bailey, A. R. & Hershon, H. I. (1976) Platelet monoamine oxidase in schizophrenia: an investigation in drug-free chronic hospitalized patients. Archives of General Psychiatry, 33, 1370–3.CrossRefGoogle ScholarPubMed
Robinson, D. S., Davis, J. M., Nies, A., Ravaris, C. L. & Sylwester, D. (1971) Relation of sex and ageing to monoamine oxidase activity of human brain, plasma and platelets. Archives of General Psychiatry, 24, 536–9.CrossRefGoogle ScholarPubMed
Sandler, M. & Reynolds, G. P. (1976) Does phenylethylamine cause schizophrenia ? Lancet, i, 70–1.Google Scholar
Schildkraut, J. J., Herzog, J. M., Orsulak, P. J., Edelman, S. E., Shein, H. M. & Frazier, S. H. (1976) Reduced platelet monoamine oxidase activity in a sub-group of schizophrenic patients. American Journal of Psychiatry, 133, 438–40.Google Scholar
Schneider, K. (1959) Clinical Psychopathology. Translated by Hamilton, M. New York: Grune and Stratton.Google Scholar
Smythies, J. R. (1976) Recent progress in schizophrenia research. Lancet, ii, 136–9.Google Scholar
Snyder, S. H., Banerjee, S. P., Yamamura, H. I. & Greenberg, D. (1974) Drugs, neurotransmitters and schizophrenia. Phenothiazines, amphetamines, and enzymes synthesizing psychotomimetic drugs aid schizophrenia research. Science, 184, 1243–53.CrossRefGoogle Scholar
Suluvan, J., Stanfield, C. N. & Dackis, C. (1977) Platelet MAO activity in schizophrenia and other psychiatric illnesses. American Journal of Psychiatry, 134, 1098–1103.Google Scholar
Takahashi, S., Yamane, H. & Tani, N. (1975) Reduction of blood platelet monoamine oxidase activity in schizophrenic patients on phenothiazines. Folia Psychiatrica et Neurologica Japonica, 29, 207–14.Google ScholarPubMed
Wing, J. K. & Brown, G. W. (1970) Institutionalism and Schizophrenia. London: Cambridge University Press.CrossRefGoogle Scholar
Wyatt, R. J. & Murphy, D. L. (1976) Low platelet monoamine oxidase activity and schizophrenia. Schizophrenia Bulletin, 2, 77–89.CrossRefGoogle ScholarPubMed
Zeller, E. A., Boshes, B., Arbit, J., Bieber, M., Blonsky, E. R., Dolkart, M. & Huprikar, S. V. (1976) Molecular biology of neurological and psychiatric disorders. 1. Effect of parkinsonism, age, sex and L-dopa on platelet monoamine oxidase. Journal of Neurotransmission, 39, 63–7.Google Scholar
Zeller, E. A., Boshes, B., Davis, J. M. & Thorner, M. (1975) Letter: molecular aberration in platelet monoamine oxidase in schizophrenia. Lancet, i, 1385.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.